NRF2 is over-activated in lung cancer either through mutations of the NRF2 encoding gene, NFE2L2, or loss-of-function mutations of KEAP1, whose protein product ubiquitinates and degrades NRF2 [25, 28, 29]. This evidence concerns the gene NFE2L2 and lung carcinoma.